‘‘SEC. 417I. BRAIN TUMOR CAR–T TEAM SCIENCE AWARD. 
‘‘(a) IN GENERAL.—In order to take advantage of 
significant advancement in the development of chimeric 
antigen receptor-T (CAR–T) cell therapy approaches in 
cancer, including many such approaches previously funded 
by the National Institutes of Health, the Director of the 
Institute shall make awards, on a competitive basis, 
through a U series funding mechanism, to support the de-
velopment of a multi-institutional team science approach 
to using CAR–T treatment for adult and pediatric brain 
tumors. 
‘‘(b) USE OF FUNDS.—Funds received through an 
award under this section shall be used— 
‘‘(1) to support collaborative multi-institutional 
research activities, including pre-clinical and inves-
tigational new drug studies; and 
‘‘(2) for the purpose of supporting clinical trials 
to evaluate CAR–T therapeutic approaches to treat-
ing brain tumors. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated $10,000,000 for each of 
fiscal years 2026 through 2030, to remain available until 
expended, to the Director of the Institute to carry out this 
section.’’. 
(b) TRANSITION FOR THE GLIOBLASTOMA THERA-
PEUTICS NETWORK.—The Director of the National Can-
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
cer Institute shall take such steps as may be necessary 
for the orderly transition from the Glioblastoma Thera-
peutics Network carried out by the Director, as of the day 
before the date of enactment of this Act, to the research 
program authorized under section 417H of the Public 
Health Service Act, as added by subsection (a). In making 
such transition, the Director shall ensure that the pro-
gram authorized under such section 417H is based upon 
and consistent with the policies and procedures of the 
Glioblastoma Therapeutics Network carried out by the Di-
rector as of the day before the date of enactment of this 
Act. 
SEC. 5. CLINICAL TRIALS AND BIOMARKER TESTING NA-
TIONAL PUBLIC AWARENESS CAMPAIGN. 
Part P of title III of the Public Health Service Act 
(42 U.S.C. 280g et seq.) is amended by adding at the end 
the following: 
‘‘SEC. 399V–8. CLINICAL TRIALS AND BIOMARKER TESTING 
NATIONAL PUBLIC AWARENESS CAMPAIGN. 
‘‘(a) NATIONAL CAMPAIGN.— 
‘‘(1) IN GENERAL.—The Secretary shall carry 
out a national campaign to increase the awareness 
and knowledge of health care providers and individ-
uals with respect to the importance of clinical trials 
in the treatment of cancer. 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(2) ACTIVITIES.— 
‘‘(A) IN GENERAL.—Activities under such 
national campaign shall include each of the fol-
lowing: 
‘‘(i) 
WRITTEN
MATERIALS.—Main-
taining a supply of written and digital ma-
terials that provide information to the pub-
lic on clinical trials, and distributing such 
materials to members of the public upon 
request. 
‘‘(ii) PUBLIC
SERVICE
ANNOUNCE-
MENTS; PUBLIC ENGAGEMENT.—Providing 
public service announcements, in accord-
ance with applicable law, including through 
publishing materials in digital or print 
form, and carrying out other public en-
gagement initiatives. Such public service 
announcements and other public engage-
ment initiatives shall include such an-
nouncements and initiatives intended to 
encourage individuals to discuss with their 
physicians— 
‘‘(I) what clinical trials are; 
‘‘(II) the importance of clinical 
trials in the treatment of cancer; 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(III) how to enroll in clinical 
trials; 
‘‘(IV) what biomarker testing is; 
‘‘(V) the importance of biomarker 
testing in the treatment of cancer; 
and 
‘‘(VI) how to access biomarker 
testing. 
‘‘(B) TARGETED POPULATIONS.—The Sec-
retary shall ensure that the national campaign 
includes communications, including public serv-
ice announcements and other public engage-
ment initiatives under subparagraph (A)(ii), 
that are— 
‘‘(i) culturally and linguistically com-
petent; and 
‘‘(ii) targeted to— 
‘‘(I) specific populations that are 
at a higher risk of cancer, including 
such populations based on factors in-
cluding race, ethnicity, level of accul-
turation, and family history; 
‘‘(II) rural communities; and 
‘‘(III) such other communities as 
the Secretary determines appropriate. 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(3) CONSULTATION.—In carrying out the na-
tional campaign under this subsection, the Secretary 
shall consult with— 
‘‘(A) health care providers; 
‘‘(B) nonprofit organizations; 
‘‘(C) State and local public health depart-
ments; and 
‘‘(D) elementary and secondary schools 
and institutions of higher education. 
‘‘(b) DEMONSTRATION PROJECTS REGARDING OUT-
REACH AND EDUCATION STRATEGIES FOR CANCER AND 
BRAIN TUMOR PATIENTS.— 
‘‘(1) IN GENERAL.—The Secretary shall carry 
out a program to award grants or contracts to pub-
lic or nonprofit private entities for the purpose of 
carrying out demonstration projects to test, com-
pare, and evaluate different evidence-based outreach 
and education strategies to increase the awareness 
and knowledge of cancer, including brain tumor bio-
marker testing and brain tumor clinical trials. Such 
projects shall focus on the awareness and knowledge 
of patients (and the families of patients), physicians, 
nurses, and other key health professionals involved 
in brain tumor treatment. 
VerDate Sep 11 2014 
02:14 Aug 22, 2024
Jkt 049200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H9113.IH
H9113
kjohnson on DSK7ZCZBW3PROD with $$_JOB